Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Meeting Abstracts

Robust T-cell responses and clinical responses following long peptide vaccination against high risk HPV-16

Cornelis J. M. Melief, M. J. P. Welters, M. J. G. Löwik, A. P. G. Vloon, J. W. Drijfhout, A. R. P. M. Valentijn, A. R. Wafelman, G. J. Fleuren, R. Offringa, S. H. van der Burg and G. G. Kenter
Cornelis J. M. Melief
Leiden University Medical Center, Leiden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. J. P. Welters
Leiden University Medical Center, Leiden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. J. G. Löwik
Leiden University Medical Center, Leiden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. P. G. Vloon
Leiden University Medical Center, Leiden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. W. Drijfhout
Leiden University Medical Center, Leiden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. R. P. M. Valentijn
Leiden University Medical Center, Leiden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. R. Wafelman
Leiden University Medical Center, Leiden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. J. Fleuren
Leiden University Medical Center, Leiden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Offringa
Leiden University Medical Center, Leiden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. H. van der Burg
Leiden University Medical Center, Leiden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. G. Kenter
Leiden University Medical Center, Leiden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published January 2008
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

A therapeutic vaccine was designed based on long overlapping peptides covering the complete amino acid sequence of the HPV16 E6 and E7 oncogenic proteins, thereby harboring all potential T helper and CTL epitopes. Previously, we demonstrated that HPV16 specific T-cell immunity induced by this vaccine delivered in Montanide ISA 51 adjuvant was able to terminate persistent infections and eradicate established HPV16+ tumors in rabbits.

Currently, 12 patients with histologically proven HPV16+ vulvar intraepithelial neoplasia (VIN) grade III were vaccinated 4 times with a 3-week interval by s.c. injection of the long peptides emulsified in Montanide ISA 51. Immunological monitoring was performed at the systemic level by the analysis of blood samples, drawn before each vaccination and after the last vaccination, and at the local level by the analysis of HPV16-specific T cells in tissue biopsies of the VIN lesion (before and after vaccination) as well as a biopsy from the last vaccination site.

In all 11 patients, already after 2 vaccinations, strong and broad vaccine-induced systemic proliferative responses accompanied with the production of IFNγ and IL-5 were detected. This type of response is similar to the memory T-cell responses observed in healthy individuals with HPV16-specific immunity. Importantly, circulating HPV16 E6 and E7 specific T-cells produced IFNγ upon stimulation with naturally processed and presented antigen. Notably, vaccination resulted in the induction of both CD4+ and CD8+ HPV16-specific T cells. Multiple epitopes were recognized in each patient. Analysis of the local immune response demonstrated the presence of HPV16-specific Th1/Th2 cells infiltrating both the vaccination site and the VIN lesion after vaccination in 6 out of 9 patients analyzed. A complete clinical response was seen in 4 out of 12 patients, as determined by complete clearance of lesions by macroscopy and microscopy. In 3 of these patients HPV 16 was also cleared as determined by PCR.

Further improvement of T-cell responses against the E7 component was achieved by delivering the E6 and E7 peptides into different SC locations, thereby avoiding immunodominance of E6 over E7.

In conclusion, our peptide-based vaccine elicits a strong and broad HPV16-specific T-cell response that displays the capacity to migrate into the persistently HPV16-infected lesion of patients with high grade VIN and causes complete regressions in a substantial proportion of patients.

This abstract was published in Cancer Immunity, a Cancer Research Institute journal that ceased publication in 2013 and is now provided online in association with Cancer Immunology Research.

 

  • Copyright © 2008 by Cornelis J. M. Melief

References

  1. 1.
    1. Dumortier H,
    2. van Mierlo GJ,
    3. Egan D,
    4. van Ewijk W,
    5. Toes RE,
    6. Offringa R,
    7. Melief CJ
    . Antigen presentation by an immature myeloid dendritic cell line does not cause CTL deletion in vivo, but generates CD8+ central memory-like T cells that can be rescued for full effector function. J Immunol 2005;175:855–863.pmid:16002683
    OpenUrlAbstract/FREE Full Text
  2. 2.
    1. Zwaveling S,
    2. Ferreira Mota SC,
    3. Nouta J,
    4. Johnson M,
    5. Lipford GB,
    6. Offringa R,
    7. van der Burg SH,
    8. Melief CJ
    . Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002;169:350–358.pmid:12077264
    OpenUrlAbstract/FREE Full Text
  3. 3.
    1. Vambutas A,
    2. DeVoti J,
    3. Nouri M,
    4. Drijfhout JW,
    5. Lipford GB,
    6. Bonagura VR,
    7. van der Burg SH,
    8. Melief CJ
    . Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. Vaccine 2005;23:5271–5280.pmid:16054734
    OpenUrlCrossRefPubMed
  4. 4.
    1. de Jong A,
    2. van Poelgeest MI,
    3. van der Hulst JM,
    4. Drijfhout JW,
    5. Fleuren GJ,
    6. Melief CJ,
    7. Kenter G,
    8. Offringa R,
    9. van der Burg SH
    . Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res 2004;64:5449–5455.pmid:15289354
    OpenUrlAbstract/FREE Full Text
  5. 5.
    1. van Poelgeest MI,
    2. Nijhuis ER,
    3. Kwappenberg KM,
    4. Hamming IE,
    5. Wouter Drijfhout J,
    6. Fleuren GJ,
    7. van der Zee AG,
    8. Melief CJ,
    9. Kenter GG,
    10. Nijman HW,
    11. Offringa R,
    12. van der Burg SH
    . Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia. Int J Cancer 2006;118:675–683.pmid:16108057
    OpenUrlCrossRefPubMed
  6. 6.
    1. van Poelgeest MI,
    2. van Seters M,
    3. van Beurden M,
    4. Kwappenberg KM,
    5. Heijmans-Antonissen C,
    6. Drijfhout JW,
    7. Melief CJ,
    8. Kenter GG,
    9. Helmerhorst TJ,
    10. Offringa R,
    11. van der Burg SH
    . Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin Cancer Res 2005;11:5273–5280.pmid:16033846
    OpenUrlAbstract/FREE Full Text
  7. 7.
    1. Melief CJ
    . Cancer immunology: cat and mouse games. Nature 2005;437:41–42.pmid:16136120
    OpenUrlPubMed
View Abstract
PreviousNext
Back to top
Cancer Immunity Archive: 8 (Suppl 1)
January 2008
Volume 8, Issue Suppl 1
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Robust T-cell responses and clinical responses following long peptide vaccination against high risk HPV-16
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Robust T-cell responses and clinical responses following long peptide vaccination against high risk HPV-16
Cornelis J. M. Melief, M. J. P. Welters, M. J. G. Löwik, A. P. G. Vloon, J. W. Drijfhout, A. R. P. M. Valentijn, A. R. Wafelman, G. J. Fleuren, R. Offringa, S. H. van der Burg and G. G. Kenter
Cancer Immun January 1 2008 (8) (Suppl 1) 2;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Robust T-cell responses and clinical responses following long peptide vaccination against high risk HPV-16
Cornelis J. M. Melief, M. J. P. Welters, M. J. G. Löwik, A. P. G. Vloon, J. W. Drijfhout, A. R. P. M. Valentijn, A. R. Wafelman, G. J. Fleuren, R. Offringa, S. H. van der Burg and G. G. Kenter
Cancer Immun January 1 2008 (8) (Suppl 1) 2;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • References
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • The collaboration for AIDS vaccine discovery: A model for accelerating research
  • Human monoclonal antibodies and analytic vaccinology
Show more Meeting Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement